Abstract A040: Interrogating the Genomic Co-Evolution of the Immune System and Prostate Cancer Along the Time and Treatment Continuum

Abstract Clonal hematopoiesis (CH) is exemplified by the expansion of genomically altered hematopoietic stem and progenitor cells that may give rise to altered immune repertoires. Driven largely by age and chronic inflammation, CH has been historically linked to myeloid malignancies. Although emerging evidence points to a modest prevalence of CH within solid tumors, the impact of these naturally occurring alterations on anti-tumor immunity and therapeutic responses remains less defined. Here, we employed somatic mutation calling algorithms to detect single nucleotide variants (SNVs) in both epithelial and immune compartments within tumors. Our preliminary analyses of single-cell RNA-sequencing (scRNA-seq) of 32 primary, therapy-naïve prostate tumors encompassing 11 patients identified conventional mutations representative of both CH and prostate cancer. Within the tumor-epithelial compartment, we identified recurrent FOXA1 class 1C mutations in 27% (3/11), alongside NCOR1 mutations in 18% (2/11), IDH1 in 9% (1/11), and SPOP in 9% (1/11) of patients. Of note, these SNVs were detected across multiple samples for the same patient. Interestingly, we also detected germline HOXB13 G84E variants, associated with increased risk for prostate cancer, in 2 cases at a high clonality within epithelial cells (>75%). CH alterations were identified in 27% (3/11) of patients based on the detection of exonic, nonsynonymous SNVs within myeloid cells. Specifically, these variants affected SF3B2 (variant allele frequency; VAF = 0.30), UBE2A (VAF = 0.30), and KMT2C (VAF = 0.43) that are predicted deleterious across multiple classifier algorithms. Patients with detectable CH alterations displayed immunologically hotter tumor microenvironments, with CH+ patients having significantly higher proportions of tumor-infiltrating monocytes (16.22% vs 7.13%, Fisher’s exact test p